Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCND1 | P24385 | 4/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379279 | 1.00 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL8123315 | 0.89 | CDK4 (0.70) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL9480597 | 0.86 | CDK4 (0.74) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL11366447 | 0.82 | CDK4 (1.00) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL2567037 | 0.81 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL4705937 | 0.81 | CDK4 (0.61) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL9178579 | 0.76 | HTR2A (0.53) | CDK4CCND1HTR2AHTR2C | |
| SCHEMBL8128124 | 0.76 | HTR2A (0.51) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL8112503 | 0.76 | HTR2C (0.63) | HTR2AHTR2CLMNAHTTKMT2A | |
| SCHEMBL1110447 | 0.75 | CDK4 (0.58) | CDK4CCND1HTR2AHTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010077839-A1 | SUBSTITUTED OXINDOL CB2 AGONISTS FOR PAIN TREATMENT | WYETH LLC (FORMERLY KNOWN AS WYETH) (US) | 2010-07-08 | — | — | WO | claimed |
| US-12599584-B2 | Indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-04-14 | — | — | US | disclosed |
| EP-3405454-B1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-12-29 | — | — | EP | disclosed |
| EP-3405454-B1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-12-29 | — | — | EP | disclosed |
| US-20210169850-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-06-10 | — | — | US | disclosed |
| US-20210169850-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-06-10 | — | — | US | disclosed |
| EP-3405454-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017125932-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017125932-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-07-27 | — | — | WO | disclosed |
| WO-2010077839-A1 | SUBSTITUTED OXINDOL CB2 AGONISTS FOR PAIN TREATMENT | WYETH LLC (FORMERLY KNOWN AS WYETH) (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-0642513-B1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | KTB TUMORFORSCHUNGSGESELLSCHAF (DE) | 2000-08-09 | — | — | EP | disclosed |
| US-5945440-A | Indolocarbazole imides and the use thereof | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
| US-5883114-A | TREATING CANCEROUS TUMORS, INFLAMMATORY DISEASES, AND ALLERGIES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | disclosed |
| EP-0642513-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993024491-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | disclosed |
| US-5081131-A | Omega-((hetero)alkyl)benz(cd)-indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4273782-A | FOR USE IN CARDIOVASCULAR DISORDERS AND COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169850-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, IDO2, INMT | CDK4 3774/4885CCND1 4267/4885HTR2A 101/4885 |
| US-12599584-B2 | Indoline derivatives, compositions comprising them and uses thereof | IL6, TNF, IDO1 | CDK4 4827/4885CCND1 3533/4885HTR2A 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.